We retrospectively reviewed the results of serial pulmonary function tests (PFT) after allogeneic bone marrow transplantation (BMT) performed in 80 children at a single institution over a 16-year period. We looked for associations linking PFT results to graft-versus-host disease (GVHD), conditioning regimen (total body irradiation (TBI) vs busulphan), and cytomegalovirus immune status. The median follow-up after BMT was 4 years. At 2 years after BMT, significant declines were found in forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), as compared to baseline. Both FEV1 and the FEV1/FVC ratio showed significantly greater reductions in the group conditioned with busulphan (n ¼ 22) than in the group conditioned with TBI (n ¼ 49) and were significantly lower in the patients with (n ¼ 16) than without (n ¼ 64) chronic GVHD. Busulphan may be associated with greater long-term lung toxicity than TBI. The relevance of this finding to selection of conditioning regimens for BMT should be examined in the light of the overall pattern of side effects. Chronic GVHD was associated with airway obstruction. total body irradiation; busulphan; cytomegalovirus Bone marrow transplantation (BMT) has been used with increasing success in children with malignant and nonmalignant haematological diseases, which cannot be cured with conventional treatment. Major advances made in recent years have sharply increased the rate of long-term relapse-free survival after BMT in children. The corollary of this progress is a need for evaluation of the long-term effects of BMT on organ system function. Chronic pulmonary disease remains a major source of morbidity and mortality in children after BMT. [1] [2] [3] [4] [5] We reviewed serial pulmonary function tests (PFT) in children treated with allogeneic BMT at a single institution over a 16-year period. We examined the relationships linking graft-versushost disease (GVHD), conditioning regimen (total body irradiation (TBI) vs busulphan), and cytomegalovirus (CMV) immune status to the development of PFT abnormalities after BMT.
Summary:
We retrospectively reviewed the results of serial pulmonary function tests (PFT) after allogeneic bone marrow transplantation (BMT) performed in 80 children at a single institution over a 16-year period. We looked for associations linking PFT results to graft-versus-host disease (GVHD), conditioning regimen (total body irradiation (TBI) vs busulphan), and cytomegalovirus immune status. The median follow-up after BMT was 4 years. At 2 years after BMT, significant declines were found in forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), as compared to baseline. Both FEV1 and the FEV1/FVC ratio showed significantly greater reductions in the group conditioned with busulphan (n ¼ 22) than in the group conditioned with TBI (n ¼ 49) and were significantly lower in the patients with (n ¼ 16) than without (n ¼ 64) chronic GVHD. Busulphan may be associated with greater long-term lung toxicity than TBI. The relevance of this finding to selection of conditioning regimens for BMT should be examined in the light of the overall pattern of side effects. Chronic GVHD was associated with airway obstruction. total body irradiation; busulphan; cytomegalovirus Bone marrow transplantation (BMT) has been used with increasing success in children with malignant and nonmalignant haematological diseases, which cannot be cured with conventional treatment. Major advances made in recent years have sharply increased the rate of long-term relapse-free survival after BMT in children. The corollary of this progress is a need for evaluation of the long-term effects of BMT on organ system function. Chronic pulmonary disease remains a major source of morbidity and mortality in children after BMT. [1] [2] [3] [4] [5] We reviewed serial pulmonary function tests (PFT) in children treated with allogeneic BMT at a single institution over a 16-year period. We examined the relationships linking graft-versushost disease (GVHD), conditioning regimen (total body irradiation (TBI) vs busulphan), and cytomegalovirus (CMV) immune status to the development of PFT abnormalities after BMT.
Patients and methods

Patient characteristics
We retrospectively reviewed PFT data from children who underwent allogeneic BMT at the Debrousse Hospital between 1984 and 2000. A total of 80 children with at least PFT performed at a year after BMT were studied. The median follow-up was 4 years and minimum follow-up was 1 year. The main patient characteristics are shown in Table 1 . Age at BMT, type of pretransplant conditioning regimen, CMV immune status of the recipient, and presence or absence of acute or chronic GVHD were recorded for statistical analyses. TBI consisted of two radiation sessions per day for 3 consecutive days, delivering 12 Gy in all. The lungs were shielded after 9 Gy. GVHD prophylaxis included cyclosporine plus methotrexate 15 mg/m 2 on day 1 after BMT and 10 mg/m 2 on days 3, 6, and 11. All the patients received cotrimoxazole for the first 12 months as Pneumocystis carinii prophylaxis. Whenever possible, PFT were obtained before BMT and yearly thereafter; however, some children were too young for PFT before BMT (Table 1) . Of 80 children, 40 were evaluable to study changes in each PFT result between baseline and 2 years after BMT (Table 1 ). In total, 80 patients were evaluable to study the relationships linking presence or absence of GVHD, pretransplant conditioning regimen (TBI vs busulphan), and CMV status to the results of each PFT over time.
Pulmonary function testing
All PFT were performed in the same laboratory. All patients tested underwent spirometry and measurement of lung volumes and carbon monoxide diffusing capacity. Spirometry was performed using a pneumotachograph (Erich Jeager, Germany) and lung volumes were determined by helium dilution techniques or body plethysmography. Diffusing capacity for carbon monoxide corrected for alveolar volume (DLCO/VA) was measured using the single breath technique, corrected for haemoglobin concentration. All lung function variables were expressed as per cent of predicted normal values. Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/ FVC, total lung capacity (TLC), and DLCO/VA were abnormal if they were below 80% of the predicted values.
Statistical methods
To analyse factors potentially associated with alterations in PFT, we evaluated several groups based on age at BMT, type of pretransplant conditioning regimen, CMV immune status, and presence or absence of acute or chronic GVHD. Changes in each PFT result between baseline and 2 years after BMT were evaluated using the paired Student's t-test. The effect of age on PFT after BMT was studied using Pearson's test and Spearman's test. Analysis of variance was used to study the relationships linking presence or absence of GVHD, pretransplant conditioning regimen (TBI vs busulphan), and CMV status to the results of each PFT over time.
Results
Clinical pulmonary events and PFT 2 years after BMT
Seven of the 80 children developed infectious pneumopathy in the first year after BMT: three interstitial pneumonitis due to CMV, four bacterial pneumonia with one due to pneumococcus. There was no alveolar haemorrhage and no intubation. Among those seven children, two had abnormal PFT at 2 years after BMT with obstructive bronchiolitis for one.
For 40 patients, PFT results at baseline and 2 years after BMT were available ( Table 2) . Among the functional parameters that were analysed, FEV1 and FVC fell significantly. FEV1 was diminished by 8% (P ¼ 0.002) and FVC by 7% (P ¼ 0.003). The DLCO/VA ratio increased significantly (20%) at 2 years after BMT (P ¼ 0.003) ( Table 2 ). Age was not significantly associated with PFT results.
Effect of CMV immune status
Of the 34 recipients with positive CMV tests before BMT, four developed CMV disease. CMV disease did not develop in any of the patients whose transplant was from a CMVpositive donor. The CMV immune status of the recipient had no influence on PFT results.
Effect of conditioning regimen
A total of 41 patients received TBI and 22 received busulphan (Table 1) . PFT results deteriorated significantly in the busulphan group (Figure 1) . The following lung function parameters were significantly lower in patients given busulphan than in those treated with TBI: FEV1, FEV1/FVC, forced expiratory flow at 25-75% of the FVC. Residual volume and residual volume/TLC were significantly higher in patients who were given busulphan.
Effect of GVHD
PFT results after BMT were not significantly different between patients with and without acute GVHD. A total of 16 patients had chronic GVHD. PFT results deteriorated significantly in this group. The following lung function parameters were significantly lower in patients with chronic GVHD: FEV1, FEV1/FVC, forced expiratory flow at 25-75% of the FVC, FVC. Residual volume, residual volume/ TLC, functional residual capacity, and airway resistance were significantly higher in patients with chronic GVHD (Figure 2) . The mean value of FEV1 and FVC in children with chronic GVHD were less than 70% predicted. The mean value of residual volume and residual volume/TLC were more than 160% predicted (Figure 2) . The FEV1/ FVC ratio decreased significantly over time in the group with chronic GVHD (Po0.005) (Figure 3 ). At 5 years after BMT, PFT were obtained in 24 patients and the mean value of FEV1/FVC was lower than 60% predicted for patients with chronic GVHD (Figure 3 ).
Discussion
In our study, PFT in 40 children deteriorated significantly during the first 2 years after BMT. In particular, significant decreases occurred in FVC and FEV1 ( 3 Cerveri et al 5 reported that 12 of 52 children had a restrictive pattern (defined as a decrease in FVC and increase in FEV1/FVC) at least 3 years after BMT. Griese et al 1 observed that PFT showed mild restrictive disease in 83 of 138 children with a median follow-up of 7 years after BMT. In a study of 27 children, Fanfulla et al 4 showed a significant FVC decline 18 months after BMT. These studies and ours provide convincing evidence that lung function deteriorates within the first few years after BMT in children. The data from the literature support a restrictive process.
We observed a significant improvement in carbon monoxide diffusing capacity at 2 years after BMT (Table 2 ). This improvement could be explained by a decreased carbon monoxide diffusing capacity before BMT due to recent chemotherapy and by absence of significant alteration of carbon monoxide diffusing capacity at 2 years after BMT. Five studies 4, [6] [7] [8] [9] found a significant decrease in this variable 8-12 months after BMT, followed by partial recovery. We cannot rule out a similar pattern in our patients, as we did not study diffusing capacity early after BMT. The previously reported transient decrease in diffusing capacity early after BMT may reflect transient interstitial lung disease.
In our study, CMV immune status of the recipient was not associated with lung function results after BMT. In earlier studies, in contrast, PFT were more likely to deteriorate when the recipient or donor was CMV positive 4 or when the recipient was CMV positive. 6 These discrepancies may be ascribable in part to the fact that we did not study donor CMV status.
For many years, TBI combined with cyclophosphamide has been the standard myeloablative regimen for patients undergoing allogeneic BMT. As an alternative to TBI, Santos et al 10 introduced busulphan in patients with acute myeloid leukaemia. Both busulphan and TBI in the conditioning regimen are known to cause lung toxicity. Busulphan has been associated with interstitial pneumopathy and other patterns of lung disease. [11] [12] [13] The lung parenchyma is highly sensitive to radiation.
14 Shielding the lungs after 9 Gy 15 and irradiating over several days in fractionated doses 16, 17 probably reduced lung toxicity in our patients, thereby contributing to preserve lung function. 18 We found that children conditioned with TBI had better preservation of lung function than those who received busulphan. In a randomized trial comparing busulphan and TBI in 187 adults and children treated with allogeneic BMT for leukaemia, Ringden et al 19 found that busulphan was associated with late toxic side effects including chronic GVHD and obstructive bronchiolitis. In high-risk patients, busulphan increased BMT-related mortality and decreased survival. 19 We found a single comparison of busulphan and TBI 2 confined to paediatric patients (n ¼ 50). PFT results were not significantly associated with the conditioning regimen, a finding ascribed by the authors to the heterogeneity of the conditioning regimens. In our study and in that by Ringden et al, 19 busulphan seemed more toxic for pulmonary function than was TBI. However, the use of TBI in children has been associated with the development of other long-term complications including cataract, 20 impaired growth, 21 endocrine dysfunction, 21 and second malignancy. 22 In our patients, chronic GVHD was associated with airflow obstruction manifesting as decreases in FEV1/FVC, FVC and FEV1 combined with increases in functional residual capacity and residual volume (Figure 2 ). Most studies support an association between GVHD and airflow obstruction. 19, [23] [24] [25] [26] [27] [28] [29] In 281 adult BMT recipients, Clark et al 24 found that chronic GVHD was a highly significant risk factor for the development of airflow obstruction. Airflow obstruction may be an indirect consequence of chronic GVHD via oesophagitis 30 with aspiration, sicca syndrome with Ig A deficiency, 31, 32 and pulmonary infections due to immunosuppression. 28 However, lung epithelial cells may also be a direct cellular target of GVHD. 28 A limitation of our study is the heterogeneity of diagnoses and conditioning regimens (Table 1) . However, this is the largest study of PFT results in children after allogeneic BMT. Our finding of greater PFT deterioration after busulphan conditioning, together with the late side effects reported by others after TBI, indicates a need for evaluating the overall effects of conditioning regimens to determine which regimen offers the best compromise between the risk of toxicity and the risk of relapse.
Adjusting the oral busulphan dosage based on early pharmacokinetic data may reduce transplant-related complications in children. 33 Chronic GVHD has been associated with obstructive lung disease in children. Close monitoring of PFT in children with chronic GVHD might ensure early detection of lung function deterioration. Highdose glucocorticoid therapy may be useful in preventing lung disease such as bronchiolitis obliterans.
Reducing long-term complications in BMT recipients is essential to improve outcomes in these children. Children with lung function alterations after BMT may be at increased risk for further impairment related to aging or to preventable factors such as smoking, air pollution, and infection. 
